CTOs on the Move

CaptureRx

www.capturerx.com

 
Founded in 2000, San Antonio-based CaptureRx is a healthcare technology company and leading 340B solution provider that puts people first, touching millions of patient lives through customer obsession and innovative products and services that support relationships among payers, providers, pharmacies and patients. Our solutions manage inventory and financial flow for 340B prescriptions filled at contract pharmacies and perform the eligibility checks required to comply with 340B program requirements. Using a process that`s seamless to the covered entity, pharmacy and patient, our Cumulus platform has processed more than 190 million patient encounters and more than 750 million switch claims. Currently, CaptureRx ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.capturerx.com
  • 219 East Houston Street Suite 200
    San Antonio, TX USA 78205
  • Phone: 888.345.6424

Executives

Name Title Contact Details

Similar Companies

Niadyne

Niadyne is a Tucson, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bio-ved Pharmaceutical Inc

Bio-ved Pharmaceutical Inc is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nivagen Pharmaceuticals, Inc.

Nivagen is engaged in the development, acquisition and sales of generic prescription drugs and over the counter products for the North American market. Our vision is to deliver high quality products at affordable prices by leveraging global partnerships with the best FDA approved manufacturing facilities across the world.

ProNAi

ProNAi Therapeutics is a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform for patients with cancer and hematological diseases. ProNAi`s lead DNAi product candidate, PNT2258, is designed to treat cancers that overexpress BCL2, an important and validated oncogene known to be dysregulated in many types of cancer. ProNAi is pursuing a multi-faceted clinical development strategy designed to efficiently achieve regulatory approval and maximize the commercial opportunity of PNT2258. ProNAi recently initiated "Wolverine", a Phase 2 trial evaluating PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma.

Broadstep

CompassionWe embrace each persons’ journey, celebrating unique perspectives and situations free of judgment.TeamworkWe are one team. We celebrate each others’ successes and work together to overcome challenges.ExcellenceWe grow with each other, so we p...